MIMEDX GROUP INC (MDXG) Stock Price, Forecast & Analysis
NASDAQ:MDXG • US6024961012
MDXG Key Statistics, Chart & Performance
The current stock price of MDXG is 4.89 USD. In the past month the price decreased by -4.86%. In the past year, price decreased by -41.82%.
MDXG Technical Analysis
MDXG Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to MDXG. While MDXG has a great health rating, its profitability is only average at the moment.
MDXG Financial Highlights
Over the last trailing twelve months MDXG reported a non-GAAP Earnings per Share(EPS) of 0.45. The EPS increased by 55.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.38% | ||
| ROA | 12.8% | ||
| ROE | 17.09% | ||
| Debt/Equity | 0.07 |
MDXG Forecast & Estimates
11 analysts have analysed MDXG and the average price target is 10.61 USD. This implies a price increase of 116.93% is expected in the next year compared to the current price of 4.89.
For the next year, analysts expect an EPS growth of 16.07% and a revenue growth 18% for MDXG
MDXG Ownership
MDXG Latest News, Press Relases and Analysis
MDXG Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 397.113B | ||
| AMGN | AMGEN INC | 17.23 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.61 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MDXG
Company Profile
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 837 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Company Info
MIMEDX GROUP INC
1775 W Oak Commons Court, Ne
Marietta GEORGIA 30062 US
CEO: Timothy R. Wright
Employees: 837
Phone: 17706519100
MIMEDX GROUP INC / MDXG FAQ
Can you describe the business of MIMEDX GROUP INC?
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. The company is headquartered in Marietta, Georgia and currently employs 837 full-time employees. The company went IPO on 2007-08-20. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The company also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
Can you provide the latest stock price for MIMEDX GROUP INC?
The current stock price of MDXG is 4.89 USD. The price decreased by -1.01% in the last trading session.
Does MDXG stock pay dividends?
MDXG does not pay a dividend.
What is the ChartMill technical and fundamental rating of MDXG stock?
MDXG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Is MIMEDX GROUP INC (MDXG) expected to grow?
The Revenue of MIMEDX GROUP INC (MDXG) is expected to grow by 18% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for MIMEDX GROUP INC?
MIMEDX GROUP INC (MDXG) currently has 837 employees.